Clinical Trials & Research

Sheaumann’s diode laser pumped 2.94 µm Er:YAG MIR-Pac laser product1,2 can be operated in the quasi-continuous-wave (QCW) pulsed mode. This mode – also known as normal-mode or long-pulse operation – sees the laser operated with pulse durations long enough for the laser to achieve steady-state operating condition. This article outlines the key characteristics of this

ABBOTT PARK, Ill., Aug. 27, 2021.  Abbott today announced results of the landmark GUIDE-HF clinical trial, a 1,000 patient randomized study designed to assess the benefits of the CardioMEMS HF System in people living with NYHA Class II, III and IV heart failure. Data adjusted for the impact of COVID-19 show a strong reduction in

Until now, patients with heart failure with preserved ejection fraction – the most common type of heart failure in the elderly – have had no access to evidenced-based treatments. For the first time, a large clinical trial led by Prof. Dr. Stefan Anker from Charité – Universitätsmedizin Berlin has identified a drug which has a

Sheaumann has successfully designed and developed the world’s first commercially available diode-laser-pumped continuously operating (CW) 1.5 W, 2.94 µm Er:YAG laser. Image Credit: Sheaumann Laser, Inc. This laser functions using the end-pumped microlaser chip configuration first documented by Chen et al.1 This configuration was later extended to incorporate other Er3+-doped garnets by Dinerman and Moulton.2

CINCINNATI, Aug. 26, 2021.  Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced dosing of the first patient on August 17, 2021 in the AT-100 (rhSP-D) Phase 1b trial in mechanically-ventilated COVID-19 patients. The clinical

In a study recently published in the journal Nature Communications, scientists have mapped the interactions between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and host RNA. They have observed that the virus heavily methylates its genome using the methylation machinery of the host RNA, leading to an improvement in viral fitness. Background Severe acute

Raman Spectroscopy is widely regarded as a useful tool, seeing frequent use in a diverse array of industries and applications; for example, medicine, pharmaceuticals, chemistry, physics, life sciences, material sciences, forensics and quality control. Image credit: Forance/Shutterstock.com Despite its progressive nature, functionality and flexibility, Raman Spectroscopy is a complex, often challenging procedure demanding a combination

SOUTH SAN FRANCISCO, August 18, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for STRO-002,

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) pandemic, gains entry into host cells through contact between projected droplets and the cells of the nose, oral cavity, or eyes. SARS-CoV-2 infectivity depends on the ability of the virus to enter host cells. The virus binds to the

The analytical detective: Benefit-risk balance and the analytical testing process The COVID-19 pandemic has emphasized the grave importance of accelerated pharmaceutical development to combat serious or life-threatening diseases and cope with medical emergencies. Image Credit: DSI, a PLG Company The FDA has four programs for these instances: fast-track designation, accelerated approval, priority review designation and

NEW YORK, Aug. 24, 2021. Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that it has enrolled and randomized over 25% of the planned 450 patients for its Phase 3 ORA-D-013-2 trial of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes

A team of scientists from France has recently conducted a simulation study to predict the impact of future epidemic waves of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the country’s healthcare system. The findings indicate that given the lower vaccine efficacy against the SARS-CoV-2 delta variant, France may face a large epidemic wave infecting

The analytical detective: Understanding impurities in the molecule assessment process Pharmaceutical companies encounter numerous challenges during drug development as they strive to demonstrate a product’s safety and efficacy. Image Credit: DSI, a PLG Company To achieve this, pharmaceutical companies must understand the complex ways in which molecules and active pharmaceutical ingredients (APIs) respond under different

Monday, August 23, 2021. Randomized, double-blind, placebo-controlled study did not meet the primary endpoint: change in the total Mayo score at week eight, relative to placebo Izencitinib was well-tolerated and safety data were consistent with expectations for this gut-selective pan-JAK inhibitor DUBLIN and SOUTH SAN FRANCISCO, Calif., /PRNewswire/ — Theravance Biopharma, Inc. (“Theravance Biopharma” or

The U.S. Food and Drug Administration (FDA) has given the first full approval to a COVID-19 mRNA vaccine, which uses modified mRNA technology invented and developed by scientists in the Perelman School of Medicine at the University of Pennsylvania, whose years of research in mRNA science laid a critical piece of the foundation for the

Monday, August 16, 2021 Phase 1 safety and immunogenicity data in individuals who received a third dose of the Pfizer-BioNTech vaccine (BNT162b2) show a favorable safety profile and robust immune responses The booster dose elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), and the Beta and Delta variants, compared to

Artificial intelligence, along with a $71-million expansion of Radiation Oncology services, is allowing UT Southwestern Medical Center cancer physicians to pioneer a new PULSAR radiation-therapy strategy that improves tumor control compared with traditional daily therapy. Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy, or PULSAR – detailed in the International Journal of Radiation Oncology, Biology, Physics – achieved

London UK and Tübingen, Germany / Boston, USA -16 August 2021 Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone Data demonstrates high protective efficacy of second-generation lead candidate, CV2CoV, in animal model during SARS-CoV-2 challenge study Neutralizing capacity

A stress signal received by the heart from fat could help protect against cardiac damage induced by obesity, a new study led by UT Southwestern researchers suggests. The finding, published online in Cell Metabolism, could help explain the “obesity paradox,” a phenomenon in which obese individuals have better short- and medium-term cardiovascular disease prognoses compared

News Clinical Trials Statement on Boosting with the Johnson & Johnson COVID-19 Vaccine NEW BRUNSWICK, N.J., August 18, 2021 – We are engaging with the U.S. FDA, CDC and other health authorities and will share new data shortly regarding boosting with the Johnson & Johnson COVID-19 vaccine. In July, Johnson & Johnson shared data demonstrating that

The United States is gearing up to provide boosters to all Americans who received the Pfizer-BioNTech and Moderna vaccines after recent reports suggested immunity wanes after 8 months. In a small study published in the medRxiv* preprint server, people given a booster Johnson & Johnson shot showed elevated and robust antibody levels. The authors write:

NEWS 18 August 2021 Health researchers report funder pressure to suppress results Small study hints that interference from bodies funding research into public-health issues such as nutrition and exercise might be more common than realized. Clare Watson 0 Clare Watson Clare Watson is a freelance science journalist in Wollongong, Australia. View author publications You can